AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
31/26/31	€0.5410	+1.88%	4,99,601
30/26/30	€0.5310	-4.67%	4,41,153
29/26/29	€0.5570	-2.11%	4,07,228
28/26/28	€0.5690	-18.48%	8,37,693
27/26/27	€0.6980	+36.59%	4,15,613

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 09:25:00 31/07/2026 pm IST			5-day change	1st Jan Change
0.5410 ^EUR	+1.88%		+3.24%	-64.78%

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	4.33Cr 4.99Cr 4.03Cr 3.7Cr 6.99Cr 476.05Cr 7.1Cr 48Cr 19Cr 237.25Cr 19Cr 18Cr 785.64Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	4.33Cr 4.99Cr 4.03Cr 3.7Cr 6.99Cr 476.05Cr 7.1Cr 48Cr 19Cr 237.25Cr 19Cr 18Cr 785.64Cr	EV / Sales 2026 *	36.1x	EV / Sales 2027 *	33.3x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib

10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/07	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
13/07	Wall Street ne chômera pas le 14 juillet
10/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
10/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	+1.88%
1 week	+3.24%
Current month	-38.87%
1 month	-38.87%
3 months	-48.77%
6 months	-61.47%
Current year	-64.78%

1 week	0.52	0.7
1 month	0.5	0.78
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.65
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%
02/02/21	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+1.88%	+3.24%	-63.64%	-85.98%	4.89Cr
MERCK & CO., INC.	+0.32%	-0.21%	+59.27%	+22.44%	32TCr
MERCK KGAA	+0.21%	+2.80%	+28.62%	-10.73%	7.15TCr
HALOZYME THERAPEUTICS, INC.	-0.91%	+2.10%	+37.38%	+89.05%	988.05Cr
KYOWA KIRIN CO., LTD.	-3.60%	-1.52%	-0.43%	-5.11%	870Cr
SK BIOPHARMACEUTICALS CO., LTD.	+1.80%	-0.88%	-20.84%	-3.30%	425.44Cr
YUHAN CORPORATION	-0.68%	+2.94%	-38.65%	+11.36%	386.28Cr
BETTA PHARMACEUTICALS CO., LTD.	+3.08%	-5.35%	-9.43%	+0.75%	347.02Cr
SUPERNUS PHARMACEUTICALS, INC.	-2.15%	-5.42%	+32.99%	+46.71%	264.72Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.85%	+5.41%	-3.94%	-4.52%	222.54Cr
Average	+0.08%	+1.83%	+2.13%	+6.07%	4.27TCr
Weighted average by Cap.	+0.21%	+4.48%	+49.67%	+17.33%

	2026 *	2027 *
Net sales	12L 13.83L 11.17L 10.26L 19.39L 13Cr 19.69L 1.32Cr 51.68L 6.58Cr 51.94L 50.85L 22Cr	13L 14.99L 12.1L 11.12L 21L 14Cr 21.33L 1.43Cr 55.99L 7.13Cr 56.27L 55.09L 24Cr
Net income	-	-
Net Debt	-	-